FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup Virtual Meeting 14 June 2013.

Slides:



Advertisements
Similar presentations
Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010
Advertisements

Legal Work Group Developing a Uniform EHR/HIE Patient Consent Form.
Medication Management
Study Objectives and Questions for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Welcome to Game Lets start the Game. An electronic health record (EHR) is a digital version of a patient’s paper chart. EHRs are real-time, patient-centered.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
© 2012 American Nurses Credentialing Center July 7, 2008 March 23, 2010 October 5, 2010 June 28, 2012 Consensus Model Affordable Care Act IOM Future of.
Information Risk Management Key Component for HIPAA Security Compliance Ann Geyer Tunitas Group
CHAPTER © 2011 The McGraw-Hill Companies, Inc. All rights reserved. 2 The Use of Health Information Technology in Physician Practices.
FDASIA Committee Background David W. Bates MD, MSc, Chair 1.
Assignment Four Underwriting. Definitions Underwriting – The process of selecting policyholders by recognizing and evaluation hazards, establishing prices.
Introduction to Regulation
Lecture 6 Personal Health Record (Chapter 16)
HITSP – enabling healthcare interoperability 1 enabling healthcare interoperability 1 Standards Harmonization HITSP’s efforts to address HIT-related provisions.
Documentation for Acute Care
Quality Assurance: Manufacturer & Clinical Aspects  Alan Cohen, M.S. DABR  Paul Naine, MSc. MIPEM  Jim Schewe, PhD, DABMP Accuray Incorporated Elekta.
RENI PRIMA GUSTY, SK.p,M.Kes
Background, Introduction, Statutory Authority, Introduction to Risk-Based Approach Larisa Rudenko, PhD, DABT.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
HIT Policy Committee Accountable Care Workgroup – Kickoff Meeting May 17, :00 – 2:00 PM Eastern.
Health Information Technology for Post Acute Care (HITPAC): Minnesota Project Overview Candy Hanson Program Manager Julie Jacobs HIT Consultant June 13,
FDASIA REGULATIONS SUBCOMMITTEE May 22, Agenda 4:00 p.m.Call to Order – MacKenzie Robertson Office of the National Coordinator for Health Information.
Risk assessment of integrated Electronic Health Records EFMI STC 2010 – 3 June 2010 Gudlaug Sigurdardottir Bjarni Thor Bjornsson.
Decision Support for Quality Improvement
FDASIA Health IT Report Jodi G. Daniel, JD, MPH Director, Office of Policy and Planning, ONC May 6, 2014.
The Use of Health Information Technology in Physician Practices
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
Optimizing Technology to Achieve Population Health Shannon Nielson, MHSA, PCMH-CCE Centerprise, Inc May 5 th, 2015 Indiana PCA Annual Conference
FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup On Site Meeting 30 May 2013.
Community Paramedic. Benchmark 101 We need a description of the epidemiology of the medical conditions targeted by the community paramedicine program.
Animal Models for Porcine Xenotransplantation Products Intended to Treat Type 1 Diabetes or Acute Liver Failure CTGTAC #47 May 14, 2009.
HIT Standards Committee Privacy and Security Workgroup: Initial Reactions Dixie Baker, SAIC Steven Findlay, Consumers Union June 23, 2009.
Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
Networking and Health Information Exchange Unit 6b EHR Functional Model Standards.
HIT Standards Committee Clinical Operations Workgroup Report Jamie Ferguson, Chair Kaiser Permanente John Halamka, Co-chair Harvard Medical School 20 August,
1 E-Health Source: Information Systems for Healthcare Management, 6th Edition Authors: Charles J. Austin and Stuart B. Boxerman Health Administration Press.
The Paradox in HIPAA Deven McGraw, JD, MPH, LLM Partner Manatt, Phelps & Phillips, LLP December 8, 2014.
CDRH INITIATIVES FOR AGING IN PLACE NIH Aging in Place Workshop September 10-11, 2014 Presented by Mary Brady, MSN, RN Senior Policy Advisor Center for.
Risk Assessments: Patient Safety and Innovation 20 May 2013.
Medicaid Fee-for-Service: Prior Authorization Criteria & the Role of the DUR Board Charles Agte, Pharmacy Administrator Health Care Services June 19, 2013.
Health Information Technology EHR Meaningful Use Milestones for HIT Funding Michele Madison
Confidential 1 HIPAA Compliance at Blue Cross Blue Shield of Minnesota: A Case Study Tim Wittenburg Director of Corporate Architecture & Data Management.
Investigational Devices and Humanitarian Use Devices June 2007.
This material was developed by Duke University, funded by the Department of Health and Human Services, Office of the National Coordinator for Health Information.
U N C H E A L T H C A R E S Y S T E M Telemedicine Sarah Fotheringham, JD Associate General Counsel, UNC Health Care
URAC Disease Management Accreditation Third National DM Summit May 13, 2003 Liza Greenberg, RN, MPH Vice President, Research and Quality.
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
Certification and Adoption Workgroup HIT Policy Committee April 28, 2014 Discussion on Incremental Rulemakings.
CDRH Advisory Committee Meeting: Orthopedic and Rehabilitation Devices Panel November 20, 2002 INDEPENDENCE™ iBOT™ 3000 Mobility System Independence Technology.
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
ICD-10 Operational and Revenue Cycle Impacts Wendy Haas, MBA, RN Dell Services Healthcare Consulting.
Health Management Information Systems Clinical Decision Support Systems Lecture b This material Comp6_Unit5b was developed by Duke University, funded by.
1 Copyright © 2009, 2006, 2003, 2000, 1997, 1994 by Saunders, an imprint of Elsevier Inc. Chapter 23 Nursing Informatics.
Advanced Healthcare Technology Management Workshop Mombasa, Kenya — 9-12 August 2006 Quality Management & HT Baset Khalaf Tshwane University of Technology.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Risk Assessment: A Practical Guide to Assessing Operational Risk
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
NPCR – Advancing E-cancer Reporting and Registry Operations (NPCR-AERRO): An Update on Innovative Activities NAACCR Annual Conference June 16, 2009 Sandy.
© 2016 Chapter 6 Data Management Health Information Management Technology: An Applied Approach.
Regulatory Updates Health Sciences Authority Singapore
Improvement Activities
The Working Group on Medical Measurements The 23rd Forum Meeting
U.S. FDA Center for Devices and Radiological Health Update
Omnibus Care Plan (OCP) Care Coordination System
Ethical Considerations for Pediatric Clinical Investigations
Tobey Clark, Director*, Burlington USA
Regulatory Perspective of the Use of EHRs in RCTs
digital FDA Bakul Patel
Presentation transcript:

FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup Virtual Meeting 14 June 2013

Follow-on Activities Reviewed/consolidated feedback and discussion points from on-site meeting Reviewed additional materials forwarded to subgroup: — Bipartisan Policy Center Health Innovation Initiative, Draft/Work-in-Progress: “Defining and Characterizing Risk of Health Information Technology” Teleconference with additional group-level discussion, consensus building

Scope Dimensions User Type ﹣ … Phases of product lifecycle ﹣ … Developer/ ‘Manufacturer’ Type ﹣ … Distribution Model ﹣ … Conditions of use ﹣ … Intended use ﹣ … Product Categories ﹣ … New as of 31 May 2013  Miscellaneous - …

User Types Health Care Providers – institutional and individual Clinical Researchers using on human subjects Patients under care by a provider General public user/consumer under own use/health management In ScopePotentially Out of Scope No Change From 31 May 2013

Product Lifecycle Design phase Implementation-Installation Maintenance Availability-Downtime Hazard Recall End-of-Life Support Cybersecurity In ScopePotentially Out of Scope New as of 31 May 2013

Product Lifecycle Design phase Implementation-Installation Maintenance Availability-Downtime Hazard Recall End-of-Life Support Cybersecurity Methods and modes of end-user training In ScopePotentially Out of Scope Consensus

Miscellaneous Regulation around Privacy (HIPAA) In ScopePotentially Out of Scope New as of 31 May 2013

Developer/ ‘Manufacturer’ Types Entity who develops/markets/licenses/distribut es products with commercial interest Entity who develops/ advertises/distributes via public channel products intended for general public users, even if no commercial interest Healthcare provider* who develops products de novo for use on patients, even if no direct or indirect commercial interest Healthcare provider* who modifies functionality of previously licensed, ‘finished’ products Individual who develops for personal private use Individual who develops/distributes via private channel to limited individuals without commercial interest In ScopePotentially Out of Scope *institutional or individual provider Clarification and refinement

Distribution Model Marketed-licensed- distributed-sold in a restricted manner, with credentialing requirements Marketed-licensed- distributed-sold in a restricted manner, without credentialing requirements Made available for download via an unrestricted public channel, with or without credentialing requirements Available under a SaaS model In ScopePotentially Out of Scope No Change From 31 May 2013

General Conditions of Use By prescription, recommendation or under direction of licensed/credentialed healthcare provider Independently by general public consumer/user For management of defined illness or chronic condition For research purposes on human subjects ? For health maintenance or fitness In ScopePotentially Out of Scope New as of 31 May 2013

General Conditions of Use Intended use Foreseeable misuse Non-foreseeable, willful misuse Use clearly beyond labeled intended use In ScopePotentially Out of Scope No Change From 31 May 2013

Specific Product Types - Categories In ScopePotentially Out of Scope

Decision Tree Approach Intended Use - Functionality – Potential for Harm

Diagram Is use intended to inform or change decision making about: - initiating - discontinuing - modifying care interventions or personal health management ? Is use intended to inform or change decision making about: - initiating - discontinuing - modifying care interventions or personal health management ? NO YES Out-of-scope … defer to existing regulatory framework Potentially in-scope

Diagram 2 Does malfunction, foreseeable misuse have potential to cause patient injury, via: Delay or failure to present clinical data/ information at time of need Presentation of outdated information Patient-data mismatch ? Does malfunction, foreseeable misuse have potential to cause patient injury, via: Delay or failure to present clinical data/ information at time of need Presentation of outdated information Patient-data mismatch ? YES NO Potentially in-scope Potentially out-of-scope

Diagram 2 Is the data/information that is managed by system the sole or 1 o source of data at point of care (i.e., no alternate sources of data / info that can be used for confirmation) ? Is the data/information that is managed by system the sole or 1 o source of data at point of care (i.e., no alternate sources of data / info that can be used for confirmation) ? YES NO Potentially in-scope Potentially out-of-scope

Diagram 2 Through design and intended use, is patient or provider reliant on data/information to initiate or modify prescribed intervention or treatment ? Through design and intended use, is patient or provider reliant on data/information to initiate or modify prescribed intervention or treatment ? YES NO Potentially in-scope Potentially out-of-scope

Examples of Scoping Using Decision Tree Approach Claims processing Health benefit eligibility Practice management / Scheduling / Inventory management Healthcare provider communication tools (e.g., , paging) Population management tools Software using historical claims data to predict future utilization/cost of care Cost effectiveness analytic software In ScopeOut of Scope

Examples of Scoping Using Decision Tree Approach Diseases severity scoring algorithms Electronic guideline distribution Disease registries In ScopeOut of Scope

Examples of Scoping Using Decision Tree Approach EHRs (installed, SaaS) Hospital Information Systems-of- systems Decision support algorithms Visualization tools for anatomic, tissue images, medical imaging and waveforms Health Information Exchanges — advanced functionality Electronic/robotic patient care assistants Claims processing Health benefit eligibility Practice management / Scheduling / Inventory management Healthcare provider communication tools (e.g., , paging) Population management tools Software using historical claims data to predict future utilization/cost of care Cost effectiveness analytic software Diseases severity scoring algorithms Electronic guideline distribution Disease registries In ScopeOut of Scope

Diagram Does product currently meet FDA (Act 21 CFR) definition of Medical Device (including MDDS) ? Does product currently meet FDA (Act 21 CFR) definition of Medical Device (including MDDS) ? NO YES Potentially in-scope

Possible revisions or re-engineering of risk assessment and regulatory framework around certain products — Currently explicitly regulated by FDA — Meet definition but through enforcement discretion, regulatory framework is not actively enforced Explicitly Enter Into Scope For Deliberation and Discussion

Examples: — Software only products — Archiving systems — MDDS — Calculators Explicitly Enter Into Scope For Deliberation and Discussion

Rationale: — Boundaries very blurred — In some cases, nearly identical functionality and risk profile for explicitly regulated and non-regulated/non-enforced products — Examples: PACS Explicitly Enter Into Scope For Deliberation and Discussion

Strive to: — develop a framework that is able to meet future undefined needs — avoid a discrete, static and specific defined list of named products Favor the decision tree approach that emphasizes functionality as a primary scoping criterion Final Conclusions

Be cautious of wide-spectrum use cases that span a risk-spectrum within a single functionality — E.g. prescribing or alerting functions, but are used on both negligible-risk and high-risk medications/drugs Consider that any products that relies on patient lookup/patient data retrieval/data- patient matching should be evaluated for risks of patient-data mismatch Final Conclusions

In preparation: — Matrix and formal decision tree tool Final one-page summary of taxonomy, process and rationale Final Conclusions

Questions and Discussion